KYLEE MALIWAUKI: Open Payments
NPI 1417622614 · PROVO, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,201 in 132 payments from 34 companies in 2025. Trend: 2023 $1,513 · 2024 $2,796 · 2025 $3,201
Food & beverage: $2,737Long term medical supply or device loan: $299Education: $165
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 20 | $608 |
| AstraZeneca Pharmaceuticals LP | 14 | $342 |
| Daiichi Sankyo Inc. | 14 | $309 |
| Merck Sharp & Dohme LLC | 8 | $195 |
| SEAGEN INC. | 2 | $165 |
| Janssen Biotech, Inc. | 7 | $160 |
| ARRAY BIOPHARMA INC | 9 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $114 |
| ABBVIE INC. | 5 | $106 |
| GlaxoSmithKline, LLC. | 5 | $83 |
Products named: Enhertu, KISQALI, KEYTRUDA, IMFINZI, SCEMBLIX, Fabhalta, TECVAYLI, CALQUENCE.
Industry payments across UT — which companies pay providers there.
